RxDoctor Payments Data

Hussein Al-Mohamad, DO

Interventional Cardiology · Blacksburg, VANPI 1598151482

Payments from drug & device makers

$2,908in general payments, 2019–2025

Across 82 payments — averaging $35.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$983
  • Abbott$680
  • Novartis$233
  • Medtronic$209
  • Shockwave Medical, Inc$170
  • Cardiovascular Systems Inc.$124
  • plus $509 from 13 others

What the payments were for

  • Food & beverage$2,908100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,908 in reported general payments places this provider in the 30th percentile of 176 interventional cardiology providers in Virginia.

See all interventional cardiology providers in Virginia

Medicare billing

Part B allowed, 2024
$211,564
Medicare patients
1,634
Services billed
3,572

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban166$185,445
EntrestoSacubitril/Valsartan35$49,747
JardianceEmpagliflozin17$21,575
XareltoRivaroxaban25$21,179
FarxigaDapagliflozin Propanediol19$17,106
BrilintaTicagrelor17$15,163
Atorvastatin Calcium122$1,577
Metoprolol Succinate83$1,057
Ranolazine ErRanolazine11$946
Amlodipine Besylate190$888
Pravastatin Sodium50$605
Metoprolol Tartrate141$581
ClopidogrelClopidogrel Bisulfate51$508
Carvedilol80$436
Losartan Potassium67$363

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$88$185,445166 claims
NovartisEntresto$233$49,74735 claims
Johnson & JohnsonXarelto$13$21,17925 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 176 interventional cardiology providers in Virginia.

Other interventional cardiology in Blacksburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →